Korro Bio (KRRO) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Korro Bio is the larger company by market cap ($155.8 million vs $141.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | RNA |
|---|---|---|
| Share price | $10.58 | $8.26 |
| Market cap | $155.80M | $141.29M |
| 1-day change | +0.86% | +4.16% |
| YTD return | +30.96% | — |
| 1-year return | -78.49% | — |
| 5-year return | -97.05% | — |
| EPS (TTM) | $-9.88 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.89 | $16.77 |
| 52-week low | $5.20 | $7.63 |
| Distance from 52-week high | -81.07% | -50.75% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +90.93% | +202.66% |
| Average volume | 148.80K | 253.00K |
| Shares outstanding | 14.73M | 17.11M |
| Employees | 57 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
KRRO vs RNA FAQ
Which is bigger, Korro Bio or Atrium Therapeutics?
Korro Bio (KRRO) is larger, with a market capitalization of $155.80M compared with $141.29M for Atrium Therapeutics (RNA).
Are Korro Bio and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.